Advertisement
Singapore markets open in 5 hours 8 minutes

  • Straits Times Index

    3,296.89
    +4.20 (+0.13%)
     

  • S&P 500

    5,058.63
    +40.24 (+0.80%)
     

  • Dow

    38,183.68
    +280.39 (+0.74%)
     

  • Nasdaq

    15,824.94
    +219.46 (+1.41%)
     

  • Bitcoin USD

    59,285.72
    +2,062.51 (+3.60%)
     

  • CMC Crypto 200

    1,273.33
    +2.59 (+0.20%)
     

  • FTSE 100

    8,172.15
    +50.91 (+0.63%)
     

  • Gold

    2,312.00
    +1.00 (+0.04%)
     

  • Crude Oil

    79.00
    0.00 (0.00%)
     

  • 10-Yr Bond

    4.5710
    -0.0240 (-0.52%)
     

  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     

  • Hang Seng

    18,207.13
    +444.10 (+2.50%)
     

  • FTSE Bursa Malaysia

    1,580.30
    +4.33 (+0.27%)
     

  • Jakarta Composite Index

    7,117.42
    -7,234.20 (-50.41%)
     

  • PSE Index

    6,646.55
    -53.94 (-0.81%)
     

Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics

Zacks Equity Research
·3-min read

Wall Street analysts forecast that Biogen Inc. (BIIB) will report quarterly earnings of $3.45 per share in its upcoming release, pointing to a year-over-year increase of 1.5%. It is anticipated that revenues will amount to $2.32 billion, exhibiting a decline of 6% compared to the year-ago quarter.

Over the last 30 days, there has been a downward revision of 0.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.

ADVERTISEMENT

Bearing this in mind, let's now explore the average estimates of specific Biogen metrics that are commonly monitored and projected by Wall Street analysts.

The combined assessment of analysts suggests that 'Revenue- Product- Spinal Muscular Atrophy- Spinraza- Total' will likely reach $422.55 million. The estimate indicates a year-over-year change of -4.7%.

Analysts expect 'Revenue- Product- Multiple Sclerosis- Tysabri- Total' to come in at $433.56 million. The estimate points to a change of -8.3% from the year-ago quarter.

Analysts' assessment points toward 'Revenue- Anti-CD20 Therapeutic Programs' reaching $421.86 million. The estimate indicates a year-over-year change of +5.6%.

The collective assessment of analysts points to an estimated 'Revenue- Product- Multiple Sclerosis- Fampyra- Total' of $19.87 million. The estimate indicates a year-over-year change of -17.6%.

Based on the collective assessment of analysts, 'Revenue- Product- Multiple Sclerosis- Tecfidera- Rest of world' should arrive at $172.03 million. The estimate points to a change of -13.9% from the year-ago quarter.

It is projected by analysts that the 'Revenue- Product- Multiple Sclerosis- Tecfidera- United States' will reach $51.79 million. The estimate indicates a year-over-year change of -30.7%.

The average prediction of analysts places 'Revenue- Product- Multiple Sclerosis- Tysabri- United States' at $228.39 million. The estimate indicates a year-over-year change of -6.9%.

The consensus among analysts is that 'Revenue- Product- Multiple Sclerosis- Tysabri- Rest of world' will reach $204.22 million. The estimate indicates a change of -10.2% from the prior-year quarter.

Analysts forecast 'Revenue- Product- Spinal Muscular Atrophy- Spinraza- Rest of World' to reach $279.27 million. The estimate points to a change of -5.8% from the year-ago quarter.

The consensus estimate for 'Revenue- Product- Spinal Muscular Atrophy- Spinraza- United States' stands at $151.01 million. The estimate suggests a change of +2.9% year over year.

According to the collective judgment of analysts, 'Revenue- Product- Multiple Sclerosis- Vumerity- United States' should come in at $117.51 million. The estimate indicates a change of +25.7% from the prior-year quarter.

Analysts predict that the 'Revenue- Product- Multiple Sclerosis- Fumarate- Rest of World' will reach $190.94 million. The estimate points to a change of -11% from the year-ago quarter.

View all Key Company Metrics for Biogen here>>>

Shares of Biogen have experienced a change of -13.7% in the past month compared to the -2.6% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), BIIB is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Biogen Inc. (BIIB) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research